back to all books

Considering the Patient in Pediatric Drug Development


Considering the Patient in Pediatric Drug Development

Starting at $127.50

Order Now

How Good Intentions Turned Into Harm


Klaus Rose

No. of pages


Year Of Issue


Paperback ISBN


eBook ISBN


About The Book

Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm¬†addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term “children” is used ambiguously to confer physiological characteristics to a chronological age limit, which in reality does not exist. This book outlines why the United States (US) and European Union’s (EU) regulatory authorities, pediatric academia, and the pharmaceutical industry demand, support and perform pediatric drug studies, along with the key flaws of this demand that blurs the different administrative and physiological meanings of the term “child.”

In addition, the book covers why most pediatric regulatory studies lack medical sense and many even harm young patients, and the conflicts of interest behind pediatric drug studies. It includes relevant information about the maturation of the human body regarding absorption, distribution, metabolism, and excretion of food and drugs as well as key differences between newborns, infants, older children, and adolescents.

My Book Store

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google